- Home
- Products
CYRAMZA (Ramucirumab Injection)
CYRAMZA (Ramucirumab Injection)
- Medicine Name: CYRAMZA
- Generic Name: Ramucirumab
- Dosage Form & Strength: Intravenous Injection – 100 mg/10 mL and 500 mg/50 mL (10 mg/mL) single-dose vials
- Manufactured By: Eli Lilly and Company
- FDA Approval Date: Yes (April 21, 2014)
CYRAMZA (Ramucirumab) is a VEGFR2 antagonist used in the treatment of various advanced or metastatic cancers. It is a monoclonal antibody that blocks angiogenesis (formation of new blood vessels) within tumors.
Approved Indications:
- Gastric or gastro-esophageal junction adenocarcinoma – as monotherapy or with paclitaxel, after progression on fluoropyrimidine- or platinum-based chemotherapy
- Metastatic non-small cell lung cancer (NSCLC) – with erlotinib (first-line, EGFR mutations) or with docetaxel (after platinum-based chemotherapy)
- Metastatic colorectal cancer – with FOLFIRI regimen following prior oxaliplatin-based therapy
- Hepatocellular carcinoma – as monotherapy in patients with AFP ≥400 ng/mL previously treated with sorafenib
Dosage:
Administered via intravenous infusion only. Not to be administered as a push or bolus. Premedication with a histamine-1 receptor antagonist is required before each infusion.
Infusion Reactions: Premedicate before infusion; reduce rate or discontinue for Grade 2–4 IRRs
Severe Bleeding: Risk of fatal hemorrhages—discontinue if severe bleeding occurs
Gastrointestinal Perforation: Permanently discontinue if a perforation occurs
Wound Healing: Avoid use within 28 days before or 14 days after major surgery
Arterial Thromboembolic Events (ATEs): Discontinue permanently in case of ATE
Hypertension: Monitor BP regularly; withhold or discontinue in case of uncontrolled hypertension
Proteinuria: Monitor urine protein levels; discontinue for nephrotic syndrome or high-grade proteinuria
Pregnancy Risk: Can cause fetal harm; use effective contraception during treatment
Documents Required for Import:
- Valid prescription from an oncologist
- Patient’s diagnostic reports
- Government-issued photo ID
- Import permit, if mandated by local law
Availability:
CYRAMZA is not commercially available in India but can be imported under the Named Patient Program. Delivery can be arranged across Mumbai, Delhi, Chennai, Hyderabad, Ahmedabad, Bangalore, Pune, and other cities.
Global Rare Meds can legally source CYRAMZA (Ramucirumab) from certified international suppliers in the USA, Europe, Canada, and Australia.
- Dispensed from our fulfillment facility in Ambernath, Thane District
- All prescriptions are reviewed by licensed pharmacists
- Delivery managed under strict cold-chain and documentation protocols across India and select global destinations
We ensure product authenticity, regulatory compliance, and safe delivery.
What is the generic name of CYRAMZA?
Ramucirumab
Who manufactures CYRAMZA?
Eli Lilly and Company
Is CYRAMZA approved by the FDA?
Yes, CYRAMZA was approved by the FDA on April 21, 2014.
What is CYRAMZA used for?
Treatment of advanced gastric, lung, colorectal, and liver cancers, depending on specific patient profiles and combination therapies.
Is CYRAMZA an immunotherapy?
Yes, CYRAMZA is a monoclonal antibody used in targeted immunotherapy.
How is CYRAMZA supplied and administered?
Supplied as 100 mg/10 mL and 500 mg/50 mL single-dose vials for IV infusion only.
What are common side effects?
Chills, hypertension, hemorrhage, proteinuria, infusion reactions, fatigue, abdominal pain, and risk of bleeding.
What are the storage conditions?
Store at 2°C to 8°C (36°F to 46°F). Do not freeze or shake. Protect from light.
Is CYRAMZA available in generic form?
No, there is currently no generic or biosimilar version of CYRAMZA available.
How do I check pricing or order CYRAMZA in India?
Contact Global Rare Meds:
Phone: +91-99675 15602
WhatsApp: +91-99675 15602
Email: info@globalraremeds.com
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
